La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Soluna Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Soluna Holdings..

Soluna Holdings (NASDAQ:SLNH) Azioni, Catena delle Opzioni

Soluna Holdings

Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.

Soluna Holdings Inc

Soluna Holdings, Inc. - 9.0% Series A Cumulative Perpetual Preferred Stock

Telsey Advisory Group analyst Dana Telsey maintains Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) with a Market Perform and maintains $52 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Oxford Industries, Maintains $52 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) with a Buy and maintains $125 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target

The MOU values Resulticks at $2 billion which will be paid for in three tranches:
(1) $1.4 billion in Diginex ordinary shares valued at $72 per share and subject to a 12-18 month lock-up, which shares will be issued at closing of the transaction;
(2) $100 million in cash that is payable within 90 business days of the closing of the transaction; and
(3) an earnout of up to $500 million payable in Diginex ordinary shares valued at $72 per share and paid in 3 independent tranches subject to Resulticks attaining at least 75% of the below audited EBITDA threshold figures:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Earnout Amount &nbsp;</td>
<td>Accounting Period &nbsp;</td>
<td>EBITDA Threshold</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>a.</td>
<td>$166,666,666</td>
<td>FY2026</td>
<td>$100,000,000</td>
</tr>
<tr>
<td>b.</td>
<td>$166,666,667</td>
<td>FY2027</td>
<td>$200,000,000</td>
</tr>
<tr>
<td>c.</td>
<td>$166,666,667</td>
<td>FY2028</td>
<td>$325,000,000</td>
</tr>
</tbody>
</table>
</figure>
Resulticks, headquartered in Singapore with operations across the United States, India, Singapore, and the Middle East, is renowned for its omnichannel client engagement automation platform. The platform leverages AI and big data analytics to deliver personalized customer experiences, enabling businesses to orchestrate seamless engagement across digital and physical touchpoints. We believe that by integrating Resulticks' cutting-edge technology, Diginex will enhance its ability to provide comprehensive data-driven sustainability solutions, thereby empowering organizations to meet evolving regulatory requirements and stakeholder expectations with greater precision and efficiency.

General

DGNX

Diginex Signed Memorandum Of Understanding For A Cash And Share Acquisition Of Resulticks At $2B

MDB: 17% &#x7C; <a href="https://www.benzinga.com//node/45780707">MongoDB shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 adjusted EPS guidance above estimates and raised its FY26 guidance. Also, the company announced an additional share repurchase authorization of $800 million.</a>
&nbsp;
VRNT: 22% &#x7C; <a href="https://www.benzinga.com//node/45780570">Verint Systems shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY26 adjusted EPS guidance above estimates.</a>
&nbsp;
LIMN: 150% &#x7C; <a href="https://www.benzinga.com//node/45781243">Liminatus Pharma Regains Nasdaq Compliance</a>

Movers

Trading Ideas

LIMN

VRNT

Market-Moving News for June 5th

Needham analyst Chris Pierce reiterates ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) from Hold to Hold.

CHPT

Needham Reiterates Hold on ChargePoint Hldgsto Hold

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/05075541/Sainte-0605-900x600-1.png" alt="" class="wp-image-13906" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/05075541/Sainte-0605-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/05075541/Sainte-0605-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/05075541/Sainte-0605-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Sainte Nutritional has filed for a Hong Kong IPO, boasting a list of heavyweight financial backers and soaring revenue and profits</li>
<li>As Chinese birthrates decline, the infant-focused maker of foods for special medical purposes is diversifying into China's growing market for elderly nutrition</li>
</ul>
When&nbsp;Sainte Nutritional Inc.&nbsp;made its first&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107416/documents/sehk25053002526.pdf">public disclosure</a>&nbsp;for a planned Hong Kong IPO last Friday, it listed Citic Securities as its main sponsor. But in an indicator of strong investor appetite for this up-and-coming maker of infant nutritional products, it revealed a short time later that CLSA would join the underwriting team as overall coordinator.
Sainte's metrics are indeed impressive for such an old-economy company with more than two decades of history. Its revenue has almost doubled over the last three years, rising from 491 million yuan ($68.3 million) in 2022 to 834 million yuan last year. Revenue from cross-border e-commerce platforms amounted to 405.1 million yuan in 2024, making up 48.6% of its total. The company's adjusted net profit has also grown quickly, from 120.7 million yuan in 2022 to 199.4 million yuan in 2024. And its gross margin has hovered at an enviable level of around 71% over the last three years.
Formerly known as Shengtong Nutritional Food, Sainte was one of China's earliest entrants in the domestic market for food for special medical purposes (FSMP), specializing mainly in specialty products for infants with allergies, which accounted for 90% of its revenues in 2024.
The domestic market that still accounts for more than half of Sainte's sales is dominated by international giants.&nbsp;Nestlé&nbsp;(NESN.SW) and&nbsp;Danone&nbsp;(BN.PA) are the country's largest and second-largest players, respectively, followed by Sainte in third and&nbsp;Abbott Laboratories&nbsp;(ABT.US) in fourth. That makes Sainte first among its domestic peers, according to third-party research in the listing document. Only one other domestic company is in the top five, dairy giant&nbsp;China Feihe&nbsp;(6186.HK).
Feihe currently trades at a price-to-sales (P/S) ratio of 2.32, meaning Sainte could fetch a valuation of about 2 billion yuan if it can match that level, based on its 2024 sales. That could help it to raise as much as 500 million yuan, if not more, giving it funds to scale up production at a new facility currently under construction in Inner Mongolia.
The IPO marks just the latest fundraising for Sainte, which also raised 400 million yuan in a Series B round in February. It boasts an A-list of backers, including SAIC Motor's Hengxu Capital investment arm, Hillhouse Capital, Lee Kai-fu's Sinovation Ventures and CICC.
FSMP products require a physician's supervision and are dominated by products for infants with special needs. In China, the penetration rate for all FSMP products is only 3%, well below the 40% rate in mature markets. According to the listing document, the Chinese market is growing 18% annually is expected to reach 53.1 billion yuan by 2029, with infant products accounting for 27.4 billion yuan, or about half the total.
The timing may be good for companies like Sainte to challenge their international peers, who could be hobbled by retaliatory tariffs from China if parts of their supply chains are based in the U.S. Sainte's only outside supplier is in South Korea, making it relatively immune from tariff wars that only affect goods imported to China from the U.S. But that said, it sells nearly half its products overseas, mostly through e-commerce, though the listing document doesn't specify how much, if any, goes to the U.S.
<h4 class="wp-block-heading">Two decades of history</h4>
Sainte's history goes back to 2005, when it was established as the FSMP division of Shengyuan Nutritional, controlled by the husband-and-wife team Zhang Liang and Meng Xiuqing. Zhang founded Synutra International in 1998 as an infant formula maker, and the company was listed on the Nasdaq from 2007 and 2017 before Zhang took it private.
China had no domestic FSMP producers in the early 2000s, according to the listing document. As the current domestic leader in the space, Sainte now has 14 product segments and seven certified products.
The strong investor interest in Sainte seems counterintuitive given China's rapidly declining birth rate. 2024, a Year of the Dragon on the Chinese zodiac and favored by prospective parents, saw an uptick in births to 9.5 million from 9 million in 2023, marking the highest number of annual births of any country in the world. Even so, the long-term outlook is bleak due to factors common to mature economies, including later marriages and the high costs of raising children. Sainte counters that China's Gen Z parents are newly committed to making sure their infants have proper nutrition and are quick to buy specialty products to address any perceived disorders.
Still, Sainte realizes the demographic trends are working against it and is diversifying into products for adults to complement its current portfolio. Demand for non-infant FSMP products is expected to boom as China's population over the age of 60 rises, already accounting for more than one-fifth of the population in 2023, based on official sources. According to Sainte's prospectus, the market for non-infant FSMP products should grow by an average annual rate of 21.5% between 2024 and 2029, reaching 25.8 billion yuan in sales by 2029.
"Guided by our ethos of ‘Precise Nutrition, Professional Care,' we care about the needs of special groups, from infants grappling with allergies, lactose intolerance and preterm vulnerabilities to the silver tsunami of the aging populace," the company said in its listing document. Sainte's 300-plus distributors sell through hospitals, postnatal care centers, specialty stores and online, with over 17,000 points of sale.
Sainte's main manufacturing facility in the Northeastern Chinese city of Qingdao, which it shared with its parent Shengyuan Group until 2023, produced 1.7 tons of FSMP products in 2024. It opened another factory in February this year, and a third is under construction in Inner Mongolia, due to open in 2026.
The company needs to move quickly as a growing field of domestic competitors nip at its heels. The annual number of new FSMP registrations in China jumped from 13 in 2022 to 70 in 2023, and another 42 registrations were recorded last year. Domestic firms accounted for 174 out of 206 FSMP registrations in China as of Sept. 20, according to the State Administration of Market Supervision, showing local Chinese companies want to try to gain a piece of this major market.
That said, the international giants still have a huge lead. Nestlé dominates with a 57% market share, followed by Danone at 18.4%. Sainte is undoubtedly hoping to wrestle some of that away for itself, and could benefit from nationalistic elements as Chinese grow increasingly comfortable with domestic brands. That could bode well for its IPO if investors believe it looks well positioned to keep up its strong growth.

Asia

IPOs

Opinion

Sainte Nutritional Files For Hong Kong IPO

Billionaires like James Murdoch, Reid Hoffman and others are throwing their weight behind a new centrist push inside the Democratic Party.
At the heart of this effort is WelcomeFest, a Washington gathering aimed at energizing moderate voices and building a structured political movement to counterbalance the party's progressive wing.
What Happened: WelcomeFest, billed as the largest public gathering of centrist Democrats, kicked off with a clear mission: to organize, energize, and empower the party's moderate wing, <a href="https://www.salon.com/2025/06/04/what-it-means-to-be-a-partisan-centrist-at-welcomefest-a-billionaire-backed-vision-for-democrats/'">the</a> Salon reports.
The initiative is led by the Welcome Party, whose co-founder, Lauren Harper Pope, described the gathering as an attempt to reflect on the 2024 cycle's overperforming Democrats and define "what it means to be a partisan centrist."
Speakers included elected officials like Sen. Elissa Slotkin (D-Mich.), Rep. Jake Auchincloss (D-Mass.), and Rep. Marie Gluesenkamp Perez (D-Wash.), alongside political commentators such as Adam Jentleson, Derek Thompson, and Matt Yglesias.
Unlike left-leaning groups that often challenge incumbents in safe districts, the Welcome Party plans to support centrist candidates in competitive areas where progressives may struggle to win general elections. Harper Pope emphasized that the group's mission is to model itself on progressive organizing strategies while targeting a different voter base.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45784755/elon-musk-who-called-trumps-one-big-beautiful-bill-a-disgusting-abomination-responds-to-coinbase-ceos-warning-that-bitcoin-could-replace-dollar">Elon Musk, Who Called Trump&#8217;s &#8216;One Big Beautiful Bill&#8217; A &#8216;Disgusting Abomination,&#8217; Responds To Coinbase CEO&#8217;s Warning That Bitcoin Could Replace Dollar If Congress Isn&#8217;t Held Accountable</a>
Why It Matters: This centrist movement is being bankrolled by a select group of influential donors. James and Kathryn Murdoch, son and daughter-in-law of billionaire media mogul Rupert Murdoch, contributed $2.5 million to the Welcome PAC in 2024.
Reid Hoffman, co-founder of LinkedIn, gave $671,000. Samuel Walton, grandson of Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) founder Samuel Walton, donated $825,000. Joshua Bekenstein, a co-chairman of Bain Capital, added another $375,000 alongside his wife.
While progressive groups like Justice Democrats boast tens of thousands of grassroots donors, Welcome PAC&#8217;s funding so far has relied on a much smaller pool of wealthy backers.
The goal, according to Harper Pope, is to craft a message that resonates with the Democratic base, nearly half of whom, according to a Gallup survey, prefer the party move closer to the center.
"We want to be representative of the party overall," she said. "If the centrist faction of the Democratic Party can be strong, robust and vibrant, it can help us not only win more elections but also help us have the liberal democracy we aspire to."
Meanwhile, Rep.&nbsp;Alexandria Ocasio-Cortez&nbsp;(D-N.Y.), a prominent figure within the left-leaning faction of the Democratic Party, is currently touring with Sen.&nbsp;Bernie Sanders&nbsp;(I-Vt), who <a href="https://www.benzinga.com/news/politics/25/06/45766354/bernie-sanders-warns-saying-trump-is-dangerous-is-not-enough-vows-to-take-on-billionaires-fight-for-working-people-and-resist-movement-towards-authoritarianism">recently criticized Democrats</a> for not having "much of a message for working people, other than to say Trump is dangerous," and wanting to <a href="https://www.benzinga.com/news/topics/25/06/45783272/bernie-sanders-says-there-is-a-new-breed-of-uber-capitalists-who-really-believe-they-are-superior-human-beings">maintain the status-quo</a>.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45786416/joe-biden-calls-trump-probe-a-distraction-from-disastrous-gop-bill-aiming-to-raise-costs-for-americans-all-to-pay-for-tax-breaks-for-the-ultra-wealthy">Joe Biden Calls Trump Probe A &#8216;Distraction&#8217; From &#8216;Disastrous&#8217; GOP Bill Aiming To Raise Costs For Americans: &#8216;All To Pay For Tax Breaks For The Ultra-Wealthy&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Billionaires Like James Murdoch And LinkedIn's Reid Hoffman Are Fueling A Centrist Reboot Of The Democratic Party

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $9 price target.

IMRX

Needham Reiterates Buy on Immuneering, Maintains $9 Price Target

Rosenblatt analyst Catharine Trebnick maintains Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Buy and maintains $12 price target.

Rosenblatt Maintains Buy on Sprinklr, Maintains $12 Price Target

<ul>
<li>New joint venture will be the owner of Kimberly-Clark's international tissue assets, including 22 manufacturing facilities, approximately 9,000 employees, and marketing and selling regional and global brands, such as Kleenex, Scott and WypAll in over 70 countries.</li>
<li>The strategic partnership will integrate Suzano's industrial and operational expertise with Kimberly-Clark´s brand management and international experience across a range of markets.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.suzano.com.br%2Fen&amp;esheet=54266377&amp;newsitemid=20250605515357&amp;lan=en-US&amp;anchor=Suzano&amp;index=1&amp;md5=52e38c7f5acfd6efcc32b04d73518baf">Suzano</a>, the world's largest pulp producer, and Kimberly-Clark, a global leader in the consumer staples industry, today announced the creation of a US$3.4 billion joint venture focused on the manufacture, marketing and distribution of consumer and professional tissue products, such as toilet paper, napkins, paper towels and facial tissues in over 70 countries. Suzano will acquire a 51 percent interest in the new entity, with Kimberly-Clark holding a 49 percent interest.
Suzano will pay Kimberly-Clark US$1.734 billion in cash for its 51 percent stake at the closing of the transaction, subject to certain customary post-closing purchase price adjustments. Closing of the transaction is contingent on, among other things, approval by regulatory and other governmental authorities, fulfillment of customary conditions precedent for transactions of this nature, and completion by Kimberly-Clarkof a corporate reorganization of its Consumer Tissue and Professional business unit. The transaction is expected to close in mid-2026 and involves approximately 9,000 employees.
The new business will be a company incorporated in the Netherlands and will include 22 manufacturing facilities located in 14 countries across Europe, Asia, including Southeast Asia, the Middle East, South America, Central America, Africa, and Oceania. Collectively, these facilities have an installed capacity to produce approximately 1 million tonnes of tissue a year. The assets to be included in the new joint venture generated net sales in 2024 of approximately US$3.3 billion.
Kimberly-Clark will retain its consumer tissue and professional businesses in the United States and its interests in existing joint ventures in Mexico, South Korea and Bahrain, among other countries.

Suzano, Kimberly-Clark Form $3.4B Global Tissue Joint Venture

Rather stagnant yet steady for years, artificial intelligence (AI) adoption spiked dramatically in mid-2023, leading to a record investment year in 2024. With one in four startups being AI companies in 2024, deals rose as a percentage of all investments, up 52%, from $86.3 billion in 2023 to $131.5 billion, according to Pitchbook.
The first quarter of 2025 started off somewhat differently, however, with the number of funded AI companies dropping, <a href="https://www.ey.com/en_us/insights/growth/venture-capital-investment-trends">according to Ernst &amp; Young</a>. Investors were more selective entering a new year, signaling a reluctance to continue to finance companies in follow-on rounds without a clear path to liquidity.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="804" height="439" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04005816/EY-Q1-2025-1.png" alt="" class="wp-image-13832" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04005816/EY-Q1-2025-1.png 804w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04005816/EY-Q1-2025-1-300x164.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04005816/EY-Q1-2025-1-768x419.png 768w" sizes="(max-width: 804px) 100vw, 804px" /></figure>
Source: Ernst &amp; Young
The total value of AI investments, however, grew last quarter and continues. Most recently, AI-powered Grammarly, with more than 40 million users and annual revenue of more than $700 million, raised $1 billion from General Catalyst.
That investment pales in comparison to recent activity in the corporate AI acquisition space. Most notably, Salesforce&#8217;s recent $8 billion dollar purchase of Informatica, a company widely regarded as a leader in AI-powered enterprise cloud data management. In addition, another technology powerhouse, IBM, and its acquisition of Seek AI, an AI platform that allows users to ask questions about enterprise data using natural language.
All this activity begs the question: What factors do investors and buyers consider when it comes to engaging with AI companies? 
<h2 class="wp-block-heading">AI Investment Considerations: VCs versus Corporate Buyers</h2>
Venture capital and corporate investor preferences in AI stocks vary based on risk appetite, investment strategies, and confidence in the future of AI technologies. However, understanding the contrasting priorities of these variables by the two investor groups provides valuable insights into the AI investment landscape.
<h2 class="wp-block-heading">VC Priorities in AI Startup Investments</h2>
Venture capitalists specialize in spotting nascent AI ventures with game-changing technologies and business models primed for rapid expansion. Their investment strategy centers on three core pillars: explosive growth potential, cutting-edge innovation, and proven market demand. This approach allows VCs to construct a varied portfolio aimed at generating substantial long-term returns. Let's delve deeper into the key factors that guide VC decision-making in AI investments:
<h3 class="wp-block-heading">1. Technological AI Innovation</h3>
VCs are drawn to technologies that have the power to disrupt existing markets or create entirely new ones. They seek unique and proprietary algorithms or methodologies that provide startups with a sustainable competitive edge. Intellectual property, including patents and trade secrets, is highly valued as it safeguards the technology from competitors.
<h3 class="wp-block-heading">2. Market Growth Potential</h3>
The question "Will this product or service sell?" is paramount. VCs assess an AI solution's market viability by evaluating the company's potential to not just survive but flourish in the marketplace. They look for evidence of product-market fit, which can be quantifiably determined by how well the startup's offering addresses market needs and solves critical problems. Early indicators of customer adoption, such as user metrics, sales figures, or successful pilot programs, are seen as positive signs of market readiness.
<h3 class="wp-block-heading">3. Exit Potential</h3>
VCs meticulously assess a startup's exit potential as a crucial factor in their investment decisions. They evaluate the likelihood of various lucrative outcomes, including the possibility of acquisition by a larger company, which can provide substantial returns. Additionally, VCs consider the startup's capability to eventually go public through an IPO, offering another avenue for significant financial gains. Beyond these exit strategies, VCs also scrutinize the startup's market positioning, looking for companies with the potential to either dominate a niche market or expand to become a major player in a broader industry. This comprehensive evaluation of exit scenarios and market potential helps VCs gauge the long-term value and return prospects of their investments in AI startups.
<h3 class="wp-block-heading">4. Portfolio Diversification</h3>
Venture capitalists employ a strategic approach to risk management by constructing diversified portfolios of AI investments. This strategy involves spreading investments across various sectors, such as healthcare, finance, and autonomous systems, among others. By diversifying across different industries and applications of AI technology, VCs aim to balance their exposure to market-specific risks and capitalize on opportunities in multiple high-growth areas. This approach not only helps to mitigate potential losses from underperforming investments but also increases the chances of capturing significant returns from breakthrough successes in different AI domains.
<h3 class="wp-block-heading">5. Cost-Effective Scalability</h3>
Venture capitalists seek assurance that a business can expand quickly with minimal additional expenses. For example, a strong and adaptable technological framework capable of managing higher demands. Additionally, a business model&nbsp;structure that enables revenue growth without a corresponding increase in costs, such as the Software as a Service (SaaS) model.
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="656" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002356/Scalability-1024x656.png" alt="" class="wp-image-13827" style="width:450px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002356/Scalability-1024x656.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002356/Scalability-300x192.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002356/Scalability-768x492.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002356/Scalability.png 1164w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Source: Andre Bourque
<h3 class="wp-block-heading">6. Team Expertise</h3>
Venture capitalists place significant emphasis on the founding team's capabilities, expertise, and vision. They typically seek teams that can effectively translate their vision into reality, demonstrating the ability to set and achieve milestones, adapt to market changes, and drive the company forward. Those with deep domain knowledge of the specific sector or problem space their AI technology addresses, ensuring a nuanced understanding of market needs. While not always mandatory, a track record of previous entrepreneurial success is highly valued. It suggests the team's ability to navigate the challenges of building and scaling a startup.
<h3 class="wp-block-heading">7. Overall Risk Assessment</h3>
Venture capitalists engage in a thorough risk assessment process as an integral part of their AI investment strategy. This multifaceted evaluation encompasses several key risk factors. Technical risk is scrutinized to determine the feasibility of developing and scaling the proposed AI technology, considering potential challenges in implementation and innovation. Market risk is carefully analyzed, focusing on the uncertainties surrounding market acceptance, competitive landscape, and the startup's ability to capture and retain market share. Additionally, VCs pay close attention to regulatory risk, particularly in the AI sector, where legal and ethical considerations can significantly impact a startup's trajectory. This includes assessing potential hurdles in data privacy, algorithmic bias, and industry-specific regulations.
<h2 class="wp-block-heading">Corporate Buyers' Strategies in AI Technology Acquisitions</h2>
Corporate buyers corporate buyers are increasingly targeting AI acquisitions that resonate with their strategic goals. Acquisition or investment positions that may enhance product offerings, accelerating innovation, or expand market reach. Acquiring AI technologies enables companies to gain a competitive edge, drive operational efficiency, and capitalize on emerging trends in AI. Here's a closer look at how these acquisitions align with various corporate objectives:
<h3 class="wp-block-heading">1. Enhancing Product Offerings</h3>
Corporate buyers leverage AI acquisitions to significantly upgrade their existing product lines. By integrating advanced AI-driven features such as predictive analytics, natural language processing, or machine learning algorithms, companies can dramatically enhance the value proposition of their offerings. This strategic move not only makes products more attractive to customers but also allows businesses to stay competitive in rapidly evolving markets. The integration of AI capabilities can transform ordinary products into smart, adaptive solutions that better meet customer needs and expectations, ultimately driving increased sales and market share.
<h3 class="wp-block-heading">2. Accelerating Innovation</h3>
AI acquisitions serve as a catalyst for innovation within corporate structures. By bringing in AI startups or technologies, companies inject fresh talent, novel ideas, and cutting-edge capabilities into their innovation pipelines. This infusion of AI expertise enables corporations to navigate the fast-paced tech landscape more effectively, facilitating quicker development and deployment of state-of-the-art solutions. The synergy between acquired AI capabilities and existing corporate resources can lead to breakthrough innovations, helping companies maintain a leading position in their respective industries and potentially disrupt markets with revolutionary products or services.
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="656" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002207/Innovation-1024x656.png" alt="" class="wp-image-13826" style="width:450px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002207/Innovation-1024x656.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002207/Innovation-300x192.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002207/Innovation-768x492.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04002207/Innovation.png 1164w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Source: Andre Bourque
<h3 class="wp-block-heading">3. Expanding Market Reach</h3>
AI technologies offer corporations powerful tools to break into new market segments and geographical regions. For instance, advanced natural language processing (NLP) capabilities can enable companies to offer their services in multiple languages, effectively expanding their global footprint. AI-driven market analysis and predictive modeling can also help identify untapped market opportunities, allowing companies to tailor their offerings to diverse customer bases. This expansion not only increases revenue streams but also diversifies the company's market presence, reducing dependence on any single market or region.
<h3 class="wp-block-heading">4. Gaining a Competitive Edge</h3>
The integration of AI technologies provides companies with a significant competitive advantage. By leveraging AI-powered predictive analytics, businesses can make more informed, data-driven decisions, staying ahead of market trends and customer preferences. Machine learning algorithms can optimize various aspects of operations, from supply chain management to customer service and personalized marketing efforts. This enhanced operational intelligence and efficiency allow companies to outperform competitors, respond more quickly to market changes, and deliver superior customer experiences, solidifying their market position.
<h3 class="wp-block-heading">5. Driving Operational Efficiency</h3>
AI acquisitions play a crucial role in streamlining business processes and driving operational efficiency. Technologies such as robotic process automation (RPA) can automate routine, repetitive tasks, freeing up human resources for more strategic activities. Machine learning algorithms can optimize resource allocation, improve forecasting accuracy, and enhance decision-making processes. These AI-driven efficiencies lead to significant cost savings, improved productivity, and better resource utilization across the organization, ultimately contributing to increased profitability and competitiveness.
<h3 class="wp-block-heading">6. Capitalizing on Emerging Trends</h3>
By acquiring AI companies or technologies, corporations position themselves at the forefront of emerging technological trends. This strategic move allows them to tap into future advancements and potentially disrupt traditional industries. For example, acquiring a company specializing in AI for healthcare could open doors to the rapidly growing fields of personalized medicine or telehealth. Such acquisitions not only provide immediate technological capabilities but also offer long-term strategic advantages, allowing companies to shape industry trends and establish themselves as leaders in emerging markets.

<h3 class="wp-block-heading">7. Intellectual Property</h3>
Acquiring AI companies provides corporations with valuable intellectual property assets, including patents, proprietary algorithms, and other innovative technologies. This bolsters the company's market position by creating significant barriers to entry for competitors. A strong IP portfolio not only protects the company's innovations but also opens up new revenue streams through licensing opportunities. Additionally, it enhances the company's attractiveness to investors and partners, potentially leading to further growth opportunities and solidifying the corporation's position as an innovation leader in its industry.
<h2 class="wp-block-heading">AI Investment Considerations Visualized</h2>
While there may be some overlap in these considerations, investors generally focus more on financial returns and market potential, while corporations prioritize strategic fit, integration, and the ability to enhance their competitive position in the market.
<figure class="wp-block-image aligncenter size-large"><img decoding="async" src="https://www.socialmarketingfella.com/wp-content/uploads/2024/07/artificial-inte_Bourque-scaled.png" alt="" style="object-fit:cover" /></figure>
Infographic by Andre Bourque comparing venture capitalists and corporations in AI investment: highlights include AI-driven innovation, exit potential, product/market fit, team expertise for VCs, and enhanced product offerings, expansion, and operational efficiency for corporations.
Feature image under DepositPhotos license
Disclosure: Adapted from the author&#8217;s blog<a href="https://www.socialmarketingfella.com/investing-in-ai-contrasting-priorities-of-vcs-and-corporate-buyers/"> SocialMarketingFella.com</a>.

Tech

How To Optimize Your AI Investment Strategy: Lessons From VCs And Corporate Buyers

Rosenblatt analyst Blair Abernethy maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $305 to $290.

Rosenblatt Maintains Buy on MongoDB, Lowers Price Target to $290

HC Wainwright &amp; Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) with a Buy rating and announces Price Target of $5.

Initiation

MIST

HC Wainwright & Co. Assumes Milestone Pharmaceuticals at Buy, Announces Price Target of $5

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.47%</li>
<li>Mizuho analyst Gabriel Moreen maintained an Outperform rating and raised the price target from $22 to $23 on May 20, 2025. This analyst has an accuracy rate of 72%.</li>
<li>JP Morgan analyst Jeremy Tonet maintained an Overweight rating and cut the price target from $25 to $23 on May 19, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 6, Energy Transfer posted downbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest ET <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0605">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0605"><img loading="lazy" decoding="async" width="911" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214755/image-64.png" alt="" class="wp-image-939023" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214755/image-64.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214755/image-64-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214755/image-64-768x701.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.51%</li>
<li>Barclays analyst Theresa Chen maintained an Overweight rating and cut the price target from $55 to $52 on May 12, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Morgan Stanley analyst Robert Kad maintained an Equal-Weight rating and raised the price target from $56 to $62 on March 11, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On May 6, MPLX posted weaker-than-expected quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0605">latest MPLX news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0605"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214837/image-65.png" alt="" class="wp-image-939025" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214837/image-65.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214837/image-65-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214837/image-65-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Hess Midstream LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESM#NYSE">HESM</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.35%</li>
<li>JP Morgan analyst Jeremy Tonet maintained a Neutral rating and raised the price target from $39 to $44 on March 27, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Citigroup analyst Spiro Dounis maintained a Buy rating and increased the price target from $41 to $44 on Feb. 18, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On May 28, Hess Midstream priced its $559.59 million secondary offering of 15,022,517 Class A shares at $37.25 each.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest HESM <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0605">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0605"><img loading="lazy" decoding="async" width="912" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214912/image-66.png" alt="" class="wp-image-939026" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214912/image-66.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214912/image-66-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04214912/image-66-768x706.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45767953/jim-cramer-arrowhead-pharmaceuticals-doesnt-have-the-horses"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45767953/jim-cramer-arrowhead-pharmaceuticals-doesnt-have-the-horses">Jim Cramer: Arrowhead Pharmaceuticals Doesn&#8217;t &#8216;Have The Horses&#8217;</a></li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

HESM

MPLX

Wall Street's Most Accurate Analysts Spotlight On 3 Energy Stocks With Over 7% Dividend Yields

MATH

Metalpha And DogeOS Unite To Drive Dogecoin's Evolution From Memecoin To Developer-Friendly Blockchain Platform

<ul>
<li>Upfront fees and near-term development milestone payments totaling up to $11 million</li>
<li>Sales milestones of $150 million or more in first 10 years of commercialization</li>
<li>Royalties equaling 25% of net sales</li>
<li>Ocugen to manufacture and supply OCU400</li>
</ul>
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP).
Pursuant to the term sheet, under the license agreement Ocugen will receive upfront license fees and near-term development milestones equaling up to $11 million. The Company will be entitled to sales milestones of $1 million for every $15 million of net sales in Korea in addition to a royalty of 25% on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement.
There are an estimated 15,000 individuals in the Republic of Korea with RP. OCU400 provides the opportunity for our partner to help thousands of patients and become a leader in gene therapy in Korea.

OCGN

Ocugen Secures Exclusive Korean Rights To OCU400 Gene Therapy For Retinitis Pigmentosa

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) with a Buy rating and announces Price Target of $14.

PHIO

HC Wainwright & Co. Assumes Phio Pharma at Buy, Announces Price Target of $14

CSTM

Constellium Partners With Nikon AM, America Makes To Unlock New Defense And Aerospace Applications For High-Performance Aheadd CP1 Alloy

Centrica and Equinor have today announced a £20 billion plus agreement to deliver gas to the UK. The new deal will see Centrica take delivery of five billion cubic meters (bcm) of gas per year to 2035.

Contracts

EQNR

Centrica, Equinor Announced £20B+ Agreement To Deliver Gas To UK

Press Releases

Soluna Reports Revenue Growth of 80.5% to $38 Million for 2024

Soluna Strengthens Texas Presence with New 120MW Wind-Powered Data Center Project

Soluna Announces Monthly Business Update

Soluna Signs Land Agreements for 166 MW Project Kati

Soluna to Expand Renewable-Powered AI & Bitcoin Computing With New 100MW Site

Soluna Signs Deal with Blockware at Project Dorothy 2, Expanding Bitcoin Hosting Business

Soluna Reports Q1'25 Results

Soluna to Launch First Solar-Powered Data Center With 75 MW Project

Blockware Expands Leadership Team and Launches Growth Division to Accelerate Bitcoin & HPC Infrastructure Innovation Ahead of Strategic Fundraising and Market Expansion

Comments

Soluna Holdings

Soluna Holdings (SLNH) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO